GENE THERAPY FOR RARE DISEASE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Market Segmentation

• By Drug (Revenue, USD Mn, 2021-2033)

  • Approved Drugs
    • • Tisagenlecleucel (Kymriah)
      • Axicabtagene ciloleucel (Yescarta)
      • Voretigene neparvovec (Luxturna)
      • Strimvelis
  • Pipeline Drugs
    • • GT-AADC
      • Fidanacogene elaparvovec (SPK-9011)
      • OTL-200
      • bb2121
      • AMT-061
      • Others

• By Therapeutic Application (Revenue, USD Mn, 2021-2033)

  • Oncology
  • Neurological Disorders
  • Ophthalmic Disorders
  • Hematological Disorders
  • Immunodeficiency Disorders
  • Metabolic Disorders
  • Others

• Global Gene Therapy for Rare Disease Market, By Region: (Revenue, USD Mn, 2021-2033)

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa